Clinical Trial Update: Dacomitinib + Pemetrexed for Patients With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC) [Phase 1]

View source ↗

Summary

Phase 1 trial investigating dacomitinib combined with pemetrexed in advanced non-squamous non-small cell lung cancer has been terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Dacomitinib (dacomitinib)
• Pemetrexed (pemetrexed)

Snippet

Sponsor: Central European Cooperative Oncology Group | Conditions: Non Small Cell Lung Cancer | Phase 1 | Status: TERMINATED | Results posted: 2019-12-30